Transforming growth factor beta 1 (TGF β1) polymorphisms and haplotype structures have dual roles in breast cancer pathogenesis.

CONCLUSION: The present study indicates that TGFB1 variants have subtype-specific roles in BC and may switch from tumor suppressor to promoter during tumor development, consistent with TGFβ1 dual role in BC pathogenesis. PMID: 29362917 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research

Related Links:

(European Society for Medical Oncology) Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Conclusion: ICC using LBC can be a useful tool in assessing biomarkers in advanced cases of breast cancer where surgery is not possible or cases where ASCO/CAP guidelines for management are not followed.
Source: Journal of Cytology - Category: Cytology Authors: Source Type: research
This article summarizes the milestones in t he development of pyrotinib leading to this first global approval for the treatment of HER2-positive advanced breast cancer.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Publication date: November 2018Source: European Journal of Surgical Oncology, Volume 44, Issue 11Author(s): Blossom Lake, Donna Appleton, Abel Zachariah, Habib Khan, Kerry Flemming, Jennifer Neill, Laura Pettit
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
An otherwise healthy 58-year-old woman with a history of breast cancer presents to the clinic with newly diagnosed metastatic disease; eventual abdominal CT showed a mass in the transverse colon with ascites and peritoneal nodularity. What is the best initial systemic treatment for her?
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
This article discusses the advances in HER2-targeted therapy, in both the metastatic and adjuvant settings, with a focus on those with early-stage breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Conditions:   HER2-positive Breast Cancer;   Breast Cancer Metastatic Interventions:   Drug: Palbociclib 75mg;   Drug: Letrozole 2.5mg;   Drug: T-DM1;   Drug: Palbociclib 100mg;   Drug: Palbociclib 125mg;   Drug: Palbociclib Sponsors:   University of Kansas Medical Center;   Pfizer Not yet recruiting
Source: - Category: Research Source Type: clinical trials
On October 16, 2018, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer Inc.), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm),...
Source: - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
Conclusion: This study unveils a potential function of Gab2 in HER2-overexpressing breast cancer cells. Gab2 might be a potential target in the clinical therapy of HER2-overexpressing breast carcinoma.Cell Physiol Biochem 2018;50:52 –65
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Authors: Petrou P Abstract INTRODUCTION: Breast cancer, the second most common cancer in women, exerts a multidimensional grave effect on affected women. Among the several sub-types of breast cancer, the overexpression of the human epidermal growth factor receptor-2 gene is associated with poorer survival and higher relapse rates. Trastuzumab, a monoclonal antibody, has proved its safety and efficacy in this specific subtype, nevertheless its high cost urges for caution among payers. Areas covered: The scope of this study is to systematically search and critically assess the economic evaluation studies of trastuzum...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Statistics | Study | Women